Regulatory Focus™ > News Articles > 6 > Recon: Amazon Buys Pharmacy PillPack for $1B

Recon: Amazon Buys Pharmacy PillPack for $1B

Posted 28 June 2018 | By Ana Mulero 

Recon: Amazon Buys Pharmacy PillPack for $1B

Welcome to Regulatory Reconnaissance, your daily regulatory news and intelligence briefing.

In Focus: US Sponsored Content: In-Depth IVDR/MDR Kick Starter Kit In Focus: International Pharmaceuticals & Biotechnology
  • Walgreens CEO: 'We're Not Worried' About Amazon's PillPack Deal (Forbes)
  • Walgreens and CVS Shares Plunge After Amazon Announces Deal to Buy Online Pharmacy PillPack (Fortune)
  • This Company Made the First FDA Approved, Marijuana Based Drug. Here's What It Wants to Do Next (Fortune)
  • Rite Aid poised to sell its first cannabis-derived drug (CNN)
  • Va. AG Herring sues Purdue Pharma, maker of Oxycontin, blaming it for opioid crisis (The Washington Post)
  • Aging HIV Population Confronts High Drug Costs, Taxes Medicare (Bloomberg)
  • As Biotech IPOs Boom Again, Here Are 5 To Watch (Forbes)
  • The Biopharmaceutical Industry Provides 75% Of The FDA's Drug Review Budget -- Is This A Problem? (Forbes)
  • It’s a record! Biotech IPO frenzy outpaces 2017 in half the time as 4 new arrivals on Nasdaq raise $556M (Endpoints)
  • Valeant signs with WorldMeds to hawk first-ever opioid withdrawal drug Lucemyra (Fierce)
  • The top 5 highest-paid women biopharma executives in 2017 (Fierce)
  • Patients who have had suicidal thoughts are often excluded from antidepressant trials. The FDA says they don’t need to be (STAT)
  • Mass. gets a thumbs-down on negotiating Medicaid prices, but Oklahoma wins on ‘value’ rebates (STAT)
  • Deloitte Survey Finds Biopharma Companies are Accelerating Adoption of Real-World Evidence (BioSpace)
  • DIA18: How much are PRVs even worth? (BioPharma Dive)
  • Opioid Makers, Blamed for Overdose Epidemic, Cut Back on Marketing Payments to Doctors (ProPublica)
  • Jaguar Health (NASDAQ: JAGX) Subsidiary Napo Pharmaceuticals and RedHill Biopharma Enter U.S. Co-Promotion Agreement for Mytesi, Napo's FDA-Approved Drug Product (Press)
Pharmaceutical and Biotechnology: Study Results, Filings and Designations
  • Newly discovered protein could boost hunt for drugs to treat sepsis and other inflammatory diseases (Fierce)
  • Sarcoma expert George Demetri grades the latest statement on Nanobiotix’s late-stage drug NBTXR3 (Endpoints)
  • Little Arsanis steers its only clinical-stage therapy to the scrap heap after a PhII implosion (Endpoints)
  • ReWalk Announces Progress in Clinical Study of ReStore Powered Exo-Suit (Press)
  • InflaRx Receives IND Approval from the FDA to Start its Phase II Clinical Trial of IFX-1 in ANCA-Associated Vasculitis (Press)
  • BRACAnalysis CDx Identifies Patients Who Respond to Lynparza in SOLO-1 Study (Press)
Medical Devices
  • Consumer DNA Testing Poses Risk for Life Insurers, Moody’s Says (Bloomberg)
  • Philips inks 11-year deal for patient monitoring as a service (Fierce)
  • Fresca Medical lands de novo authorization for Curve positive airway pressure system (MobiHealthNews)
  • Medtronic wins $472m cardio device DoD contract (MassDevice)
  • Study: Leadless pacers lead to less complications (MassDevice)
  • Kent Imaging inks wound care imaging deal with SerenaGroup (MassDevice)
  • Medtronic Launches the MiniMed(TM) 670G System Performance Guarantee for Payers and Employers (Press)
  • LabCorp and Philips collaborate on digital pathology to enhance the efficiency of pathology diagnostics (Press)
US: Assorted & Government
  • U.S. jury orders DaVita to pay $383.5 million in wrongful death lawsuits (Reuters)
  • The politics of pre-existing conditions (Axios)
  • Insurance start-up launches on-demand health coverage (CNBC)
  • Texas Democrat: Medicare Negotiations Will Lower Drug Prices (Bloomberg)
  • Oklahoma Medicaid Policy Could Create Bigger Rx Rebates (Bloomberg)
  • The Food and Drug Administration’s Comprehensive, Multi-Year Nutrition Innovation Strategy; Public Meeting; Request for Comments (FDA)
Upcoming Meetings & Events Europe
  • ThromboGenics to change name (The Pharma Letter)
  • EU freezing UK out of drug safety scheme after Brexit (pharmaphorum)
  • NHS England expands health and care record scheme (PharmaTimes)
  • Brexit is bad for Britain’s health, doctors say (The Guardian)
  • Can Technology Save U.K. Perinatal Care? (Forbes)
  • EMA stakeholder engagement report 2017 (EMA)
  • Alexion Submits Application for Approval of ALXN1210 as a Treatment for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) in the European Union (EU) (Press)
  • AI ambulances and robot doctors: China seeks digital salve to ease hospital strain (Reuters)
  • C-Bridge hands Nuance Biotech $35M, opening doors to more China licensing deals (Endpoints)
  • Weight-loss drug Saxenda creates marketing sensation in Korea (Korea Biomedical Review)
  • Korean pharmaceuticals fail to invalidate Invokana patent (Korea Biomedical Review)
India Australia
  • 'Three parent baby' IVF technique on track to become legal in Australia (The Sydney Morning Herald)
  • NSW Environment Minister calls on PM to ban toxic firefighting foam (The Sydney Morning Herald)
  • Australia wins landmark WTO ruling on plain tobacco packaging (Reuters)
  • MA welcomes medicines shortages legislation in Australia (The Pharma Letter)
  • How Australia’s largest pharmacy group protects customer medical record and data (OpenGov)
  • Novaliq’s NovaTears Treatment for Evaporative Dry Eye Disease is Now Available across Australia and New Zealand (Press)
  • Drug Pricing in Canada • Aging and HIV • A Biotech Beats Goliath (Bloomberg)
  • Google sister-company Sidewalk has a secret 'yellow book' with its plans to reinvent cities, plus possible sites beyond Toronto (CNBC)
  • Drug makers in Canada disclose doctor payments as transparency debate heats up (The Globe and Mail)
General Health & Other Interesting Articles
  • Feeling poorly? The app will see you now (Reuters)
  • Health care start-up says A.I. can diagnose patients better than humans can, doctors call that 'dubious' (CNBC)
  • AI can make health care smarter, more cost-effective (Politico)
  • Subscribing to Your Patients — Reimagining the Future of Electronic Health Records (NEJM)
Regulatory Reconnaissance is our daily intelligence briefing for the regulatory affairs space, bringing you the top regulatory news stories from around the globe. Each weekday morning, we aim to bring you the latest highlights of new approvals, meetings, legal and political developments, regulations and guidance, and the latest trends with the potential to impact regulatory affairs professionals and the industry in which they work.
Need to contact the editor of Regulatory Reconnaissance? Email us at

A story's inclusion in Regulatory Reconnaissance does not imply endorsement by Regulatory Focus or RAPS.

Categories: Recon

Regulatory Focus newsletters

All the biggest regulatory news and happenings.